A B S T R A C T

Polycystic ovary syndrome is the most common endocrine disorder among women of reproductive age. Although traditionally viewed as a reproductive disorder, there is increasing appreciation that it is associated with significantly increased risk of cardiometabolic disorders. Women with polycystic ovary syndrome may present to clinicians via a variety of different routes and symptoms. Although the impact on reproduction predominates during the reproductive years, the increased cardiometabolic problems are likely to become more important at later stages of the life course. Women with polycystic ovary syndrome have an approximately 2- to 5-fold increased risk of dysglycaemia or type 2 diabetes, and hence regular screening with oral glucose tolerance test is warranted. Although the diagnostic criteria for polycystic ovary syndrome are still evolving and are undergoing revision, the diagnosis is increasingly focused on the presence of hyperandrogenism, with the significance of polycystic ovarian morphology in the absence of associated hyperandrogenism or anovulation remaining uncertain. The management of women with polycystic ovary syndrome should focus on the specific needs of the individual, and may change according to different stages of the life course. In view of the clinical manifestations of the condition, there is recent debate about whether the current name is misleading, and whether the condition should be renamed as metabolic reproductive syndrome.
that the Rotterdam criteria should be adopted for now because it is the most inclusive. Using the Rotterdam criteria, many patients can be diagnosed based on the history and physical examination (e.g., a history of irregular menses, and clinical signs of hyperandrogenism). The panel also suggested that the disorder should be renamed to more adequately reflect the complex metabolic, hypothalamic, pituitary, ovarian, and adrenal interactions that characterise the syndrome. A previous local study by Lam et al. comparing the different diagnostic criteria in Hong Kong Chinese women concluded that the Rotterdam criteria are generally applicable to our population. Nevertheless, recent discussion has centred on the importance of hyperandrogenism, and emerging evidence suggests that women with radiological evidence of polycystic ovaries, but no other clinical features of PCOS, represent a population generally of lower risk who are distinct from other women with PCOS who fulfil current diagnostic criteria.

Pathogenesis

To date, the pathophysiology of PCOS remains unclear; yet, substantial evidence suggests it is a multifactorial condition, where interactions between endocrine, metabolic, genetic, and environmental factors intrinsic to each other act in consonance towards a common result (Fig 2). Also, the heterogeneity of PCOS further reinforces its multifactorial nature. Although familial segregation of cases suggests a genetic component in this syndrome, most of the susceptibility genes and single-nucleotide polymorphisms remain to be discovered. Among its diverse phenotypes, hyperandrogenism and ovarian dysfunction are recognised as the two main features of PCOS. Hyperandrogenism in PCOS is recognised as the excessive androgen biosynthesis, use, and metabolism. When the ovaries are stimulated to produce excessive amounts of androgen, an accumulation of numerous follicles or cysts can be observed in the ovary. Insulin resistance is also a major cause of hyperandrogenism in PCOS, through stimulating the secretion of ovarian androgen and inhibiting hepatic sex hormone–binding globulin (SHBG) production. Approximately 80% to 85% of women with clinical hyperandrogenism have PCOS. Women with PCOS and hyperandrogenism may experience excess hair growth, acne, and/or abnormal folliculogenesis. Three major pathophysiological pathways have been described, but they are not mutually exclusive. They are ovulatory dysfunction, disordered gonadotropin release, and insulin resistance.

Disordered gonadotropin release and excess androgen release

In PCOS, hypersecretion of luteinising hormone (LH) can lead to an increase in androgen production by the ovarian thecal cells. This is thought to be due to increased gonadotropin-releasing hormone (GnRH) pulse frequency, resulting in increased frequency and pulsatile secretion of LH, and increased levels of LH relative to follicle-stimulating hormone (FSH) in the circulation. There also appears to be resistance to the negative feedback by progesterone to the GnRH pulse generator, which is often present by puberty. The increased LH/FSH ratio, along with some ovarian resistance to FSH, results in excess production of androgens from thecal cells in ovarian follicles, leading to impaired follicular development, and reduced inhibition of the GnRH pulse generator by progesterone, thereby setting up a vicious cycle...
TABLE 1. Summary of proposed diagnostic criteria for PCOS in adults6-9 *

<table>
<thead>
<tr>
<th>Criteria</th>
<th>National Institutes of Health (1990)6</th>
<th>Rotterdam (2003)—diagnosis established if 2 out of 3 criteria are met7</th>
<th>Androgen Excess and PCOS Society (2009)—diagnosis requires hyperandrogenism with 1 of 2 remaining criteria8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperandrogenism</td>
<td>• Acne or hirsutism or androgenic alopecia and/or Biochemical hyperandrogenism • Elevated serum androgen level (total testosterone or bioavailable testosterone or free testosterone)†</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>Oligo-anovulation</td>
<td>• &lt;8 Menstrual cycles per year, or frequent bleeding at intervals &lt;21 days, or infrequent bleeding at intervals &gt;35 days • Mid-luteal progesterone documenting anovulation</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>Polycystic ovary</td>
<td>• &gt;12 Follicles of 2-9 mm in diameter in at least one ovary (without a cyst or dominant follicle), and/or • Ovarian volume &gt;10 mL</td>
<td>Not required</td>
<td>+/-</td>
</tr>
</tbody>
</table>

Abbreviation: PCOS = polycystic ovary syndrome

* Legend: + indicates an essential criterion for diagnosis; +/- indicates clinical features that are one of the criteria which may need to be present for the diagnosis to be established

† Given the variability in testosterone level and the suboptimal standardisation of assays, it is difficult to define an absolute level that is diagnostic of PCOS or other causes of hyperandrogenism, and the Task Force recommends familiarity with cut-offs of local assays9

---

FIG 2. Pathophysiology of polycystic ovary syndrome

Abbreviations: DHEAS = dehydroepiandrosterone sulfate; FSH = follicle-stimulating hormone; GnRH = gonadotropin-releasing hormone; IGF-1 = insulin-like growth factor 1; IGFBP-1 = insulin-like growth factor–binding protein-1; LH = luteinising hormone; PCOM = polycystic ovarian morphology; SHBG = sex hormone–binding globulin; TG = triglycerides
that exacerbates the hypersecretion of LH, and ovulatory dysfunction.14,19,20

Ovulatory dysfunction

Unlike the ovarian follicular development in healthy women, in PCOS cases, follicle growth is disrupted due to ovarian hyperandrogenism, hyperinsulinaemia from insulin resistance, and intra-ovarian paracrine signalling. Hyperinsulinaemia further impairs follicle growth by amplifying LH-stimulated and insulin-like growth factor 1 (IGF-1)–stimulated androgen production.21–24 Hyperinsulinaemia also elevates serum free testosterone levels through decreased hepatic SHBG production, and enhances serum IGF-1 bioactivity through suppression of IGF-binding protein production.25 Insulin excess also promotes premature follicle luteinisation through enhanced FSH-induced granulosa cell differentiation, which arrests granulosa cell proliferation and subsequent follicle growth.26 Finally, overproduction of anti-Müllerian hormone (AMH)27–29 by the granulosa cells of ovarian follicles in PCOS appears to antagonise FSH action in small PCOS follicles.30 The relatively lower FSH levels contribute to arrested follicular development in the ovary, leading to amenorrhoea, anovulation, and polycystic morphology.8,16

Insulin resistance

In PCOS cases, there is an increased level of bioavailable androgens that leads to increased insulin resistance in peripheral tissues (mostly in the skeletal muscle).31 Insulin resistance causes compensatory hyperinsulinaemia and might contribute to hyperandrogenism and gonadotropin aberrations through several mechanisms. Insulin may act directly in the hypothalamus, the pituitary or both and thereby contribute to abnormal gonadotropin levels. By facilitating the stimulatory role of LH, hyperinsulinaemia leads to further increase in ovarian androgen production in theca cells.32 High insulin can also serve as a co-factor to stimulate adrenocorticotropic hormone–mediated androgen production in the adrenal glands.33 Moreover, an insulin-induced decrease in the production of SHBG in the liver increases the amount of free bioavailable androgens.34

Most women with PCOS, particularly those who are overweight or obese, do in fact have insulin resistance and compensatory hyperinsulinaemia,35,36 partly attributable to an intrinsic insulin resistance mechanism.37–38

Using the homeostasis model assessment, 50% to 70% of women with PCOS demonstrate insulin resistance. Using the gold standard technique of euglycaemic hyperinsulinaemic clamp, it was found that PCOS exhibits insulin resistance that is independent of obesity, and is present even among lean patients with PCOS, but this is further exacerbated in the presence of obesity.39,40

A stepwise increase in the prevalence of glucose intolerance with increasing body mass index (BMI) has been described in cross-sectional studies performed in women with this disorder.41 Although most women with PCOS have normal insulin secretory responsiveness, studies have suggested that PCOS women, particularly those with a family history of type 2 diabetes (T2D), have impaired β-cell function or a subnormal disposition index (an index of β-cell function that takes insulin resistance into account).16,42,43

Adipose dysfunction

Although the full molecular mechanisms underlying insulin resistance in PCOS remain unclear, primary defects in insulin-mediated glucose transport,44 GLUT4 production,45 and insulin or adrenergic regulated lipolysis46 in adipocytes (and sometimes in myocytes and fibroblasts) have been reported. Insulin resistance in PCOS contributes to the dysfunctional adipogenesis to some degree from an impaired capacity of regional adipose tissue storage to properly expand with increased dietary caloric intake.47–49 Adipose tissue secretes numerous factors to regulate metabolic function, appetite, neural activity, and digestion. This tissue is also heavily infiltrated by macrophages, and a crosstalk exists between adipocytes, macrophages, and pluripotent cells for complex paracrine interactions. It is known that dysregulation of adipokine production, such as adiponectin, by macrophage-secreted cytokines in PCOS facilitates the development of insulin resistance.50 Other adipokines including leptin, retinol-binding protein 4, and visfatin have also been implicated.51 Improved understanding of the underlying mechanisms that govern adipose tissue dysfunction and insulin resistance in PCOS would be beneficial in the identification of novel therapeutic targets for PCOS and other related disorders.52

Intrauterine environment

In humans, rhesus monkeys and sheep, inappropriate testosterone exposure during fetal life alters the developmental trajectory of the female leading to PCOS-like phenotypes, such as phenotypic masculinisation; reproductive, neuroendocrine, ovarian disruptions; and hyperinsulinaemia.52 In a human study, it has been shown that there is an increased prevalence of PCOS in women with classic CAH and congenital adrenal virilising tumours.53 In one human study, higher testosterone levels compared with those usually observed in normal females were found in the umbilical vein of female infants born to mothers with PCOS;54 yet, another prospective study that investigated the relationship between prenatal androgen exposure and the
The development of PCOS in female adolescence did not confirm any association between these variables.\(^{55}\)

Excess fetal exposure to maternal androgens is thought to contribute to induction of the PCOS phenotype in offspring/children. Nonetheless, more clinical studies are needed to confirm the role of intrauterine androgen exposure on human fetal development.

**Recent insights from genetic studies**

Polycystic ovary syndrome has a high heritability of approximately 80%. Although a large number of candidate gene studies have been conducted, no genetic variants have been found to be consistently associated with PCOS. Recent hypothesis-free genome-wide association studies using high-density genotyping arrays that systematically investigate common variants across the genome have identified several genetic loci to be significantly associated with PCOS (Table 2).\(^{56}\) These have shed light on the important role of the gonadotropin axis in the pathogenesis of PCOS, as well as several other novel pathways, including epidermal growth factor signalling. Interestingly, genetic studies have revealed a significant overlap of findings when different diagnostic criteria of PCOS have been applied, highlighting greater homogeneity than previously appreciated.\(^{16,56,57}\)

**Clinical features and co-morbidities**

**Gynaecological and reproductive dysfunction**

Menstrual dysfunction is common and is characterised by oligomenorrhoea and, less often, amenorrhoea. Nonetheless, menstrual problems are frequently neglected and anovulatory infertility is frequently the initial complaint for which the patient seeks medical advice. Women with PCOS have an increased risk of miscarriage, gestational diabetes, pre-eclampsia, and preterm labour.\(^{58-60}\) A meta-analysis highlighted that the risks of gestational diabetes, pregnancy-induced hypertension, and pre-eclampsia are approximately 3-fold, whereas the risk for preterm labour is approximately 2-fold among women with PCOS.\(^{58}\) The reasons for the adverse pregnancy outcomes are unclear, but hypersecretion of LH, hyperandrogenaemia and hyperinsulinaemia have all been postulated. Due to anovulatory dysfunction and consequent long-term unopposed oestrogen stimulation, PCOS patients are at increased risk of endometrial cancer.\(^{61,62}\) Nonetheless, there is currently no consensus to support routine biopsy or ultrasound of the endometrium for endometrial hyperplasia or cancer screening in asymptomatic women due its poor diagnostic accuracy.\(^{63}\)

### Table 2. Genetic loci associated with polycystic ovary syndrome discovered in genome-wide association studies\(^ {56}\)

<table>
<thead>
<tr>
<th>Chromosome</th>
<th>Nearest gene</th>
<th>GWAS top SNP</th>
<th>Odds ratio</th>
<th>P value</th>
<th>Discovery population</th>
<th>Replicated population(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2p16.3</td>
<td>LHCGR</td>
<td>rs13405728</td>
<td>1.41</td>
<td>7.55 x 10^-21</td>
<td>Chinese</td>
<td>Europeans, Indians</td>
</tr>
<tr>
<td>2p16.3</td>
<td>FSHR</td>
<td>rs2268361</td>
<td>1.15</td>
<td>9.89 x 10^-13</td>
<td>Chinese</td>
<td>Europeans, Arabs, Chinese</td>
</tr>
<tr>
<td>2p21</td>
<td>THADA</td>
<td>rs13429458</td>
<td>1.49</td>
<td>1.73 x 10^-23</td>
<td>Chinese</td>
<td>Europeans, Chinese</td>
</tr>
<tr>
<td>2q34</td>
<td>ERBB4</td>
<td>rs1351592</td>
<td>1.18</td>
<td>1.2 x 10^-12</td>
<td>Chinese</td>
<td>-</td>
</tr>
<tr>
<td>5q31.1</td>
<td>RAD50</td>
<td>rs13164856</td>
<td>1.13</td>
<td>3.5 x 10^-4</td>
<td>Chinese</td>
<td>-</td>
</tr>
<tr>
<td>8p32.1</td>
<td>GATA4</td>
<td>rs804279</td>
<td>1.35</td>
<td>8.0 x 10^-10</td>
<td>Chinese</td>
<td>-</td>
</tr>
<tr>
<td>9q33.3</td>
<td>DENND1A</td>
<td>rs2479106</td>
<td>1.34</td>
<td>8.12 x 10^-19</td>
<td>Chinese</td>
<td>Europeans</td>
</tr>
<tr>
<td>9q22.32</td>
<td>C9orf3</td>
<td>rs4385527</td>
<td>1.19</td>
<td>5.87 x 10^-4</td>
<td>Chinese</td>
<td>Europeans</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs3802457</td>
<td>1.30</td>
<td>5.28 x 10^-14</td>
<td>Chinese</td>
<td>-</td>
</tr>
<tr>
<td>11p14.1</td>
<td>FSHB</td>
<td>rs11031006</td>
<td>1.16</td>
<td>1.9 x 10^-4</td>
<td>European</td>
<td>Europeans, Chinese</td>
</tr>
<tr>
<td>11q22.1</td>
<td>YAP1</td>
<td>rs1894116</td>
<td>1.27</td>
<td>1.08 x 10^-22</td>
<td>Chinese</td>
<td>Europeans, Chinese</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs11225154</td>
<td>1.22</td>
<td>7.6 x 10^-11</td>
<td>European</td>
<td>Chinese</td>
</tr>
<tr>
<td>12q14.3</td>
<td>HMGA2</td>
<td>rs2272046</td>
<td>1.43</td>
<td>1.95 x 10^-21</td>
<td>Chinese</td>
<td>Europeans</td>
</tr>
<tr>
<td>12q13.2</td>
<td>RAB5B/SUOX</td>
<td>rs705702</td>
<td>1.27</td>
<td>8.64 x 10^-26</td>
<td>Chinese</td>
<td>Europeans</td>
</tr>
<tr>
<td>12q21.2</td>
<td>KRR1</td>
<td>rs1275468</td>
<td>1.13</td>
<td>1.9 x 10^-4</td>
<td>Europeans</td>
<td>-</td>
</tr>
<tr>
<td>16q12.1</td>
<td>TOX3</td>
<td>rs4784165</td>
<td>1.15</td>
<td>3.64 x 10^-11</td>
<td>Chinese</td>
<td>Europeans</td>
</tr>
<tr>
<td>19p13.3</td>
<td>INSR</td>
<td>rs2059807</td>
<td>1.14</td>
<td>1.09 x 10^-4</td>
<td>Chinese</td>
<td>Europeans</td>
</tr>
<tr>
<td>20q13.2</td>
<td>SUMO1P1</td>
<td>rs6022786</td>
<td>1.13</td>
<td>1.83 x 10^-4</td>
<td>Chinese</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations: GWAS = genome-wide association study; SNP = single-nucleotide polymorphism
**Endocrine dysfunction**

Women with PCOS have varying degrees and manifestations of androgen excess. Clinical signs of hyperandrogenism include acne, hirsutism, male-pattern hair loss, and/or elevated serum androgen concentrations. Hirsutism is the most common symptom of hyperandrogenism, affecting up to 70% of women with PCOS. It is commonly noted on the upper lip, chin, periareolar area, in the mid- sternum, and along the linea alba of the lower abdomen. There is substantial ethnic variation in hirsutism where Asian women with PCOS have a lesser degree of hirsutism. Signs of more severe androgen excess—such as deepening of the voice, breast atrophy, and clitoromegaly—occur rarely and suggest the possibility of ovarian hyperthecosis or an androgen-secreting tumour.

**Metabolic dysfunction and cardiovascular risks**

Polycystic ovary syndrome is associated with cardiovascular risk factors, including obesity, hypertension, glucose intolerance, dyslipidaemia, and obstructive sleep apnoea. The high prevalence of metabolic disturbances and the consequent increase in the long-term risk of T2D indicate that PCOS should be considered a general health problem rather than just a reproductive syndrome. Most investigators found that at least one half of PCOS women are obese. The prevalence of obesity in PCOS varies widely with the population studied, similar to the wide variability in prevalence of obesity in the general population.

Insulin resistance occurs in 60% to 80% of women with PCOS, and 95% of obese women with PCOS. The risk of T2D is increased in PCOS, particularly in women with a first-degree relative with T2D. In a systematic review, it was estimated that the prevalence of impaired glucose tolerance and T2D was as high as 31% to 35%, and 7.5% to 20%, respectively, in women with PCOS by their fourth decade, and the risks were significantly higher at all ages and all weights even in young or lean subjects with PCOS. In Hong Kong, the prevalence of T2D under 35 years old is 0.6% in the general population, but 7.5% in women with PCOS.

Dyslipidaemia is the most common metabolic abnormality in PCOS. Most studies of women with PCOS have demonstrated low high-density lipoprotein cholesterol and high triglyceride concentrations, consistent with their insulin resistance, as well as an increase in low-density lipoprotein cholesterol.

Metabolic syndrome, characterised by a cluster of cardiometabolic risk factors associated with insulin resistance, is a disease with a large health impact as it confers a 5-fold increase in risk of T2D and a 2-fold increase in risk of cardiovascular diseases. A cross-sectional study evaluated the cardiometabolic risk factors in 295 Hong Kong Chinese women with PCOS with a mean age of 30 years. It found that the prevalence of metabolic syndrome in this cohort was 24.9% despite their relatively young age, a 5-fold increase in risk compared with women without PCOS even after controlling for age and BMI. In another study involving 170 Asian women with PCOS, metabolic syndrome as defined according to the International Diabetes Federation criteria was present in 35.3% of the subjects.

The prevalence of non-alcoholic fatty liver disease (including non-alcoholic steatohepatitis), and obstructive sleep apnoea is also increased in women with PCOS. Even after controlling for BMI, women with PCOS are still 30 times more likely to have sleep-disordered breathing and 9 times more likely than controls to have daytime sleepiness.

The presence of obesity, insulin resistance, impaired glucose tolerance (or T2D), and dyslipidaemia may predispose women with PCOS to coronary heart disease. An excess risk of coronary heart disease or stroke in women with PCOS, however, is not well established due to the lack of long-term prospective studies. Available studies are mostly too small to detect differences in event rates, and none have shown an evident increase in cardiovascular events. Therefore, the focus has been on risk factors of cardiovascular disease although these may not necessarily equate with events or mortality. Studies have found that women with PCOS have an increased carotid intima media thickness and coronary artery calcification, the two major surrogate markers for atherosclerotic cardiovascular disease. Serum concentrations of C-reactive protein, a biochemical predictor of cardiovascular disease, also appear to be commonly elevated in women with PCOS.

**Patient evaluation**

**Clinical features**

The history-taking should include detailed inquiry about growth and sexual development, menstrual pattern, reproductive history, medical and drug history, symptoms of androgen excess, co-existing cardiovascular risk factors such as tobacco and alcohol use, and family history. Drug history is important as a history or current use of sodium valproate has been shown to be associated with PCOS.

During the physical examination, it is essential to search for signs of androgen excess (hirsutism, acne, androgenic alopecia) and insulin resistance (acanthosis nigricans). Modified Ferriman-Gallwey scoring is the method generally used to evaluate clinical hirsutism, but is affected by subjective
variability and cosmetic treatments. It has been suggested that in East Asian patients, a lower cut-off of the modified Ferriman-Gallwey score (of 3) should be used instead of the usual cut-off of 8.16.19 As cosmetic hair removal is common in many Asian countries, evaluation of hirsutism should always include enquiry about any previous hair-removal procedures. Assessment of blood pressure, BMI, and waist circumference is also essential. Features of virilisation, Cushing's syndrome, and thyroid dysfunction should also be looked for and excluded.19

**Biochemical features**

Laboratory measurements should include tests to achieve the diagnosis, exclude other endocrine problems, and evaluate cardiovascular risk factors. In someone with clinical signs of hyperandrogenism, one could argue that biochemical testing is not necessary according to current diagnostic criteria. Most expert groups, however, suggest measuring total testosterone concentration in women who present with hirsutism. Women with PCOS mostly have high-normal or borderline elevated levels of testosterone.

Elevated total testosterone is the most direct evidence for androgen excess, but it is important to note that most assays are relatively inaccurate at the lower levels present in females, and use of mass spectrometry–based assays of total testosterone are more accurate and preferred.9 Measurement of free testosterone is a more sensitive test, but commercially available free testosterone assays are often unreliable. The free testosterone index, calculated by total testosterone divided by SHBG, is considered more reliable but is not routinely performed due to the high cost of measuring SHBG.9 Serum LH and FSH levels should be measured at the early follicular phase of the menstrual cycle. Ovulatory assessment such as mid-luteal progesterone measurement is sometimes required in patients seeking infertility treatment. In rare instances where there are rapidly progressive features of hyperandrogenism, virilising symptoms, or markedly elevated androgen levels (such as a serum testosterone >5 nmol/L), additional investigations may be indicated, including checking cortisol, dehydroepiandrosterone sulfate, and imaging of the adrenal glands and ovaries. As mentioned earlier, AMH is implicated in the pathogenesis of PCOS, and recent studies have highlighted its potential utility in the diagnosis of women with PCOS,16 although no diagnostic cut-off value has been defined yet due to the heterogeneity between the different AMH assay methods.

Blood tests to exclude other endocrine problems include thyroid function tests, prolactin, or tests to exclude other underlying causes of excess androgens, including 17-hydroxyprogesterone to exclude late-onset CAH and the 1-mg overnight dexamethasone suppression test to exclude Cushing’s syndrome. It is sometimes noted that women with PCOS have mildly elevated prolactin.20 If the level of 17-hydroxyprogesterone is borderline elevated, a short synacthen test with measurement of 17-hydroxyprogesterone may be indicated to exclude late-onset CAH.19

Assessment of cardiovascular risk factors includes an oral glucose tolerance test (OGTT) and fasting lipid profiles. Fasting glucose, although more convenient, has been shown to underestimate diabetes prevalence and cardiovascular risk when compared with OGTT, particularly in obese subjects. Measuring fasting glucose alone is therefore inadequate for the assessment of dysglycaemia in women with PCOS.84 Patients with normal glucose tolerance should be re-screened at least once every 2 years, or more frequently if additional risk factors are identified. Patients with impaired glucose tolerance should be screened annually for development of T2D.

**Ultrasound features**

The use of ultrasound in the diagnosis of PCOS must be tempered by an awareness of the broad spectrum of women with ultrasonographic findings characteristic of polycystic ovaries.85 If the patient has both oligo-ovulation and hyperandrogenism, a transvaginal ultrasound to document polycystic ovaries is not necessary according to the Rotterdam criteria. In women who are ready to conceive, ultrasound can be used to monitor and document ovulation.

The ultrasound criteria in the diagnosis of PCOS have evolved since the first ultrasound description of polycystic ovaries in 1986.8 The Rotterdam criteria described polycystic ovaries as the presence of ≥12 follicles in each ovary measuring 2 to 9 mm in diameter and/or increased ovarian volume of >10 mL. One ovary fulfilling this definition is sufficient to define polycystic ovaries. More recently, it has been proposed that if newer technology such as ultrasound machines with transducer frequency of ≥8 MHz are available, then raising the follicle number per ovary to 25 for diagnosing PCOS would be more specific.86

Ultrasoundography is operator-dependent and requires expertise. Transvaginal ultrasound is the method of choice, but is practically difficult in patients without previous sexual experience. Transrectal ultrasound examination is an alternative in women where transvaginal scan is not possible. Transabdominal ultrasound has poorer resolution, especially in obese subjects. Recent research suggests that ultrasound might be useful to supplement the diagnosis in the event of ovulatory disturbance without hyperandrogenism.82,86,87
Treatment approach

The management of women with polycystic ovary varies according to the main symptoms and primary problem experienced by the patient. The particular needs of the patient may change according to different stages of the life course, from adolescence through to reproductive age.88 Hence management should involve a multidisciplinary approach involving paediatricians, gynaecologists, endocrinologists, family physicians, dietitians, clinical psychologists, and surgeons, as appropriate.84

Management of menstrual irregularity

Menstrual irregularity is one of the most common presenting symptoms of patients with PCOS, and often reflects underlying ovarian dysfunction and anovulation. Chronic anovulation and secondary amenorrhoea can be associated with endometrial hyperplasia and increased risk of endometrial carcinoma, along with other complications associated with amenorrhoea including osteoporosis. Overweight women with PCOS should be encouraged to lose weight; as low as a 5% reduction in body weight is associated with improvement in amenorrhoea.88-90 Previous studies have highlighted that a lifestyle modification programme is associated with improvement in menses, hirsutism, biochemical hyperandrogenism, and insulin resistance.89,91

Progestagens can be administered both as a diagnostic test to induce progesterone withdrawal, as well as to treat amenorrhoea. Cyclical progestagens, preferably given 12 to 14 days per month, can be used to ensure regular withdrawal bleeding to avoid endometrial hyperplasia, and are associated with less-adverse cardiometabolic effects than combined oestriadiol-progestagen pills. Periodic short courses of progestogen (2-3 monthly) are an alternative option.

The use of the combined oral contraceptive (COC) pill, with its beneficial effects on suppressing excess androgen and its manifestations, has been a commonly used and convenient treatment for amenorrhoea, with the added benefit of providing contraception. In women with PCOS, COC formulations containing less androgenic progestagens are preferred. Nonetheless, there has been some debate about whether the use of COC may cause exacerbation of cardiometabolic risk.92 Contra-indications to use of a COC include heavy smokers aged ≥35 years, those with hypertension or established cardiac disease, and those with multiple cardiovascular risk factors.93 Nevertheless, current recommendations suggest that this is a useful alternative, although clinicians should monitor for changes in body weight, blood pressure, lipid profile as well as dysglycaemia if patients are prescribed COC, especially if the patient is overweight.

Management of hyperandrogenism

As highlighted earlier, administration of an oestrogen-containing oral contraceptive has beneficial effects on hyperandrogenism. Furthermore, the oral contraceptive pill containing the anti-androgenic progestagen cyproterone acetate, administered in cyclical doses, or drospirenone-containing COC might be beneficial for hirsutism.16 The use of cyproterone-containing pills to alleviate hyperandrogenic symptoms should ideally be limited to short-term use and discontinued 3 to 4 months after symptom resolution due to higher thromboembolic risk than the first-line COC pills.94 Other anti-androgens, such as finasteride, are sometimes used in severe cases of hirsutism, although again patients need to ensure they avoid conceiving whilst on anti-androgenic drugs.

In most circumstances, women may elect to use cosmetic measures to treat the clinical manifestations of hyperandrogenism. Different cosmetic approaches for hair removal—including shaving, waxing, and electrolysis—have variable efficacy and duration of effects. Laser therapy in the form of photoepilation represents a more permanent solution but is also more costly.8 Other options for treatment of hirsutism due to hyperandrogenism include use of topical efalornithine that may help reduce excess facial hair.

Management of anovulatory infertility

The presence of anovulatory infertility can be investigated by measurement of progesterone in the mid-luteal phase of the menstrual cycle (eg day 21 of a 28-day cycle, or day 28 of a 35-day cycle), and can help to establish the presence of anovulation. The monitoring of basal body temperature to confirm ovulation does not predict ovulation reliably, and is no longer recommended.95 In patients with anovulatory infertility, clomiphene treatment is usually considered the first-line treatment. Clomiphene should be started at a low dose (eg 50 mg daily for 5 days per cycle) and gradually increased until the lowest effective dose that achieves ovulation is reached, but this requires close monitoring, especially for the potential side-effects of multiple pregnancy and ovarian hyperstimulation. Treatment can be repeated if unsuccessful, but the majority of patients who respond usually do so within the first three cycles.96,97 The highest recommended dose for clomiphene is 150 mg, and if the woman still does not respond, second-line treatment should be considered.

Metformin has beneficial effects on anovulation. In a systematic review and meta-analysis, metformin was found to be associated with increased success at inducing ovulation.98 Doses vary in clinical trials from 1 g daily to higher doses. In a multicare
randomised controlled trial, therapy-naïve PCOS women who received metformin had a significantly lower live birth rate than women who conceived through clomiphene alone, or were treated with a combination of clomiphene and metformin. The use of metformin as a co-treatment with clomiphene has been shown to improve ovulation in women with clomiphene-resistant PCOS. Metformin is in general stopped after successful conception, although some advocate continued use during the first trimester to reduce the risk of spontaneous miscarriage. This is still an area of controversy, and the pros and cons of continuing metformin should be carefully discussed. Metformin is known to cross the placenta but it has also been shown to be a useful treatment for gestational diabetes.

Aromatase inhibitors reduce circulating oestrogen levels, lead to a rise in pituitary FSH, and have previously shown beneficial effects in a meta-analysis. Letrozole, an aromatase inhibitor, was found to be superior to clomiphene in achieving live births in a randomised clinical trial.

Daily injections of exogenous gonadotropins, including recombinant FSH or menopausal gonadotropin, have been found to improve ovulation induction among women who did not respond to other treatments. This treatment requires careful monitoring, and should be used with a ‘chronic low-dose step-up’ approach as outlined by the ESHRE/ASRM to avoid multiple pregnancies or ovarian hyperstimulation syndrome.

**Ovarian surgery/drilling/laparoscopic ovarian diathermy**

Surgical procedures such as ovarian wedge resection or ovarian drilling by diathermy or laser lead to a decreased number of antral follicles, reduced ovarian androgen production, and improved ovulation. Ovarian wedge resection is no longer performed due to the higher extent of adhesion formation and ovarian tissue damage. Ovarian drilling has been used as an alternative to exogenous gonadotropins for treatment of anovulatory infertility, with similar success rates. The main limitations include the potential for formation of adhesions, and reduced ovarian reserve. In a retrospective analysis of Chinese women with PCOS treated by laser diathermy, spontaneous ovulation rates and cumulative pregnancy rates were similar regardless of the presence or absence of metabolic syndrome.

**Assisted reproductive procedures**

In women who fail second-line treatment such as metformin, ovarian drilling or ovarian stimulation with gonadotropins, third-line treatment such as intrauterine insemination or in-vitro fertilisation can be considered.

**Management of cardiometabolic risk**

Women with PCOS are at substantially increased cardiometabolic risk, and therefore should undergo periodic evaluation of associated risk factors. Overweight women with PCOS should undergo comprehensive evaluation by a dietitian, and be encouraged to lose weight. Weight loss of approximately 5% is already associated with improved metabolic parameters as well as reproductive outcome. Even among women with normal BMI, those with PCOS appear to have increased visceral adiposity that contributes to the endogenous insulin resistance, and is correlated with metabolic parameters, fatty liver as well as carotid intimal-medial thickness.

In addition to lifestyle measures, women should be screened for glucose intolerance by an OGTT. Screening using fasting glucose alone is inadequate in this high-risk population. Presence of impaired glucose tolerance may warrant treatment with metformin given the multiple metabolic and reproductive benefits, regardless of whether there is clinical evidence of insulin resistance. Overt diabetes should be treated using an appropriate combination of dietary treatment, metformin, other oral glucose-lowering agents, and in some cases, insulin. The choice of agent should depend on the underlying pathophysiology (eg whether obesity is present), but also take into account the fertility wishes and plans of the patient. Metformin in combination with lifestyle intervention has been found to be associated with greater reduction in BMI compared with lifestyle intervention alone.

Several studies have demonstrated the efficacy of thiazolidinediones in improving metabolic parameters as well as menses and hyperandrogenism in women with PCOS. Due to possible adverse effects, however, this class of agent is currently not recommended for treatment of insulin resistance among women with PCOS.

Treatment of hypertension likewise should take into account the fertility wishes of the patient. Screening for other secondary causes of young-onset hypertension may be necessary, especially if atypical features such as proteinuria are present. Preferred anti-hypertensive agents in women contemplating pregnancy would be the older agents such as methyldopa. It is notable that women with pre-existing hypertension are more likely to develop hypertension-related complications during pregnancy, and therefore require more strict surveillance during pregnancy. Hyperlipidaemia can be managed using dietary measures, and in some cases, lipid-lowering agents such as HMG CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors. If there are plans for pregnancy, drug treatment with lipid-lowering treatment should be withheld.
Psychological distress, anxiety, and depression are common among women with PCOS, and may be linked to some of the skin complications such as hirsutism and acne or presence of menstrual and fertility problems; all these impact on psychological well-being. Clinicians need to have a high level of awareness and screen for these symptoms when appropriate and offer the necessary referrals for psychological support. Sleep-disordered breathing including obstructive sleep apnoea is also common, impacts sleep quality, and can exacerbate both mood problems as well as cardiometabolic risk. It should be screened for and managed accordingly. In those with marked obesity, bariatric surgery is an option to address obesity and associated metabolic abnormalities. Interestingly, a systematic review including 13 primary studies found that the incidence of PCOS was reduced from 45.6% to 7.1% after bariatric surgery.105

The screening and management of metabolic abnormalities is particularly relevant in those women with PCOS who are planning a pregnancy or undergoing fertility treatment. Women with PCOS are at increased risk of different complications including gestational diabetes and pre-eclampsia. Undiagnosed gestational diabetes/maternal hyperglycaemia or poorly controlled blood pressure all contribute to poorer pregnancy outcome among women with PCOS. Optimal management before pregnancy and intrapartum can help to minimise the risk of these pregnancy complications.

Conclusions
Polycystic ovary syndrome is a multi-faceted syndrome that is becoming increasingly recognised, and is an important contributor to multiple medical and reproductive problems. As illustrated in this review, given the multiple reproductive and metabolic complications associated with PCOS, patients may seek medical attention via a variety of different channels, and may present to clinicians through different disciplines. Clinicians therefore need to recognise the multi-faceted nature of this complex disorder and be aware of the associated complications. Diagnostic criteria are still evolving, although currently the Rotterdam criteria remain the most widely accepted. Given the burden of metabolic complications associated with the disorder, there has been much recent discussion regarding the potential need to rename the syndrome to better highlight its metabolic consequences, in addition to the known reproductive features. The long-term risks of the different complications are still not clearly defined, given the scarcity of well-conducted prospective studies. These limitations in our current knowledge highlight the need to follow-up this group of high-risk women.

Acknowledgement
RCW Ma acknowledges support from the Research Grants Council General Research Fund (Ref. 14110415).

Declaration
All authors have disclosed no conflicts of interest.

References
14. Cheung LP. Polycystic ovary syndrome: not only a


